文献速递淋巴瘤造血干细胞移植与细胞治疗

儿童、青少年和年轻成人淋巴瘤自体血液或骨髓移植后的晚期疾病负担与死亡风险:BMTSS报告

Late morbidity and mortality after autologous blood or marrow transplantation for lymphoma in children, adolescents and young adults-a BMTSS report.
PubMed 文献 · Leukemia · 2024-02-19

研究纳入583例40岁前因淋巴瘤接受自体血液或骨髓移植且移植后存活≥2年的患者(霍奇金淋巴瘤59.9%,非霍奇金淋巴瘤40.1%)及1070例对照,中位随访9.8年。幸存者发生3-4级慢性健康问题的调整比值比约为对照的3倍(95%CI 2.3-4.1)。移植时年龄>30岁、移植前放疗及移植年份<1990与3-5级问题风险升高相关,作者呼吁基于风险的长期随访。

要点

  • 40岁前因淋巴瘤接受自体移植后存活≥2年者,3-4级慢性健康问题调整OR约为对照的3倍(95%CI 2.3-4.1)。
  • 移植时年龄>30岁者3-5级问题风险升高(aHR 2.31,95%CI 1.27-4.19,参照≤21岁)。
  • 移植前放疗者3-5级问题风险升高(aHR 1.52,95%CI 1.13-2.03,参照未放疗者)。

核心结论

  • 40岁前因淋巴瘤接受自体血液或骨髓移植后,晚期疾病负担与死亡风险较高,作者呼吁开展基于风险的长期前瞻性随访。

研究设计与样本

  • 队列研究纳入583例40岁前因淋巴瘤接受自体血液或骨髓移植且移植后存活≥2年的患者(霍奇金淋巴瘤59.9%,非霍奇金淋巴瘤40.1%)及1070例对照。
  • 参与者自报社会人口学信息与慢性健康问题,采用CTCAE v5.0对健康问题进行严重程度评分(3级严重、4级危及生命、5级致命)。
  • 采用逻辑回归估计幸存者与对照发生3-4级问题的比值比,采用比例次分布风险模型识别移植受者中3-5级问题的预测因素。
  • 移植时中位年龄30.0岁(范围2.0-40.0),中位随访9.8年(范围2.0-32.1)。

主要发现

  • 幸存者发生3-4级问题的调整比值比约为对照的3倍(95%CI 2.3-4.1)。
  • 移植时年龄>30岁者发生3-5级问题的aHR为2.31(95%CI 1.27-4.19,参照≤21岁)。
  • 移植前放疗者发生3-5级问题的aHR为1.52(95%CI 1.13-2.03,参照未放疗者)。
  • 移植年份≥2000者发生3-5级问题的aHR为0.54(95%CI 0.34-0.85,参照<1990年)。
  • 复发相关死亡与非复发相关死亡的25年累积发生率分别为18.2%和25.9%。

临床怎么用

  • 作者认为,40岁前因淋巴瘤接受自体血液或骨髓移植后晚期疾病负担与死亡风险较高,呼吁开展基于风险的长期前瞻性随访。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We determined the risk of late morbidity and mortality after autologous blood or marrow transplantation (BMT) for lymphoma performed before age 40. The cohort included autologous BMT recipients who had survived ≥2 years after transplantation (N = 583 [HL = 59.9%; NHL = 40.1%]) and a comparison cohort (N = 1070). Participants self-reported sociodemographics and chronic health conditions. A severity score (grade 3 [severe], 4 [life threatening] or 5 [fatal]) was assigned to the conditions using CTCAE v5.0. Logistic regression estimated the odds of grade 3-4 conditions in survivors vs. comparison subjects. Proportional subdistribution hazards models identified predictors of grade 3-5 conditions among BMT recipients. Median age at BMT was 30.0 years (range: 2.0-40.0) and median follow-up was 9.8 years (2.0-32.1). Survivors were at a 3-fold higher adjusted odds for grade 3-4 conditions (95% CI = 2.3-4.1) vs. comparison subjects. Factors associated with grade 3-5 conditions among BMT recipients included age at BMT (>30 years: adjusted hazard ratio [aHR] = 2.31; 95% CI = 1.27-4.19; reference: ≤21 years), pre-BMT radiation (aHR = 1.52; 95% CI = 1.13-2.03; reference: non-irradiated), and year of BMT (≥2000: aHR = 0.54; 95% CI = 0.34-0.85; reference: <1990). The 25 years cumulative incidence of relapse-related and non-relapse-related mortality was 18.2% and 25.9%, respectively. The high risk for late morbidity and mortality after autologous BMT for lymphoma performed at age <40 calls for long-term anticipatory risk-based follow-up.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Holmqvist AS, Meng Q, Dai C, et al. Late morbidity and mortality after autologous blood or marrow transplantation for lymphoma in children, adolescents and young adults-a BMTSS report. Leukemia. 2024. PMID: 38374408. doi:10.1038/s41375-024-02144-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。